The ALFA study is a long term, prospective, observational study of AD patients' adult children aimed at studying and characterizing key physio-pathological features of the preclinical phase of AD.
Eligibility
Sex
ALL
Min age
45 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol).
* Age: 45 to 64 years old.
* Long-term commitment to the study: baseline and follow-up visits. Potential participants have to agree to undergo to all the procedures described in the protocol.
Exclusion Criteria:
* Cognitive impairment: to be included the participant must show no signs of objective cognitive impairment.
* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
* Illiteracy or functional illiteracy.
* Any contraindication to any test or procedure at the time of study inclusion.
* Family history of monogenic AD.
* Not willing to undergo one or more of the tests and procedures described in the protocol at baseline.
Primary outcome measure(s)
Change from preclinical phase of AD to Mild Cognitive Impairment. — Every 3 years, from date of inclusion until the date of first documented progression, fulfilling mild cognitive impairment criteria, or date of death from any cause, whichever came first, assessed up to 12 years.
Trial sites (1)
Facility
City
Region
Status
Barcelonabeta Brain Research Center
Barcelona
Spain
More Barcelonabeta Brain Research Center, Pasqual Maragall Foundation trials in Spain
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
